Dosage & Administration
fluocinolone acetonide 0.59 MG Drug Implant [Retisert]
NO BLACK BOX WARNING
Dosage & administration
* RETISERT is surgically implanted into the posterior segment of the affected eye through a pars plana incision. (2.1)
* RETISERT is designed to release fluocinolone acetonide at a nominal initial rate of 0.6 mcg/day, decreasing over the first month to a steady state between 0.3-0.4 mcg/day over approximately 30 months. (2.1)
* Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure. (2.2)
Retisert prescribing information
Need to report a Retisert issue?
Report adverse event
You can report a Retisert adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
Check Drug Interactions
Can't find what you're looking for?
Our trained staff can help you:
See Coverage Restrictions
Get Prior Authorization Forms
Get Affordability Enrollment Forms
Request Patient Education Materials
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.